Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 279

1.

Using neuroimaging to investigate the impact of Mandolean® training in young people with obesity: a pilot randomised controlled trial.

Hinton EC, Birch LA, Barton J, Holly JMP, Biernacka KM, Leary SD, Wilson A, Byrom OS, Hamilton-Shield JP.

BMC Pediatr. 2018 Nov 22;18(1):366. doi: 10.1186/s12887-018-1342-1.

2.

Circulating Growth and Sex Hormone Levels and Breast Tissue Composition in Young Nulliparous Women.

Denholm R, De Stavola BL, Hipwell JH, Doran SJ, Holly JMP, Folkerd E, Dowsett M, Leach MO, Hawkes DJ, Dos-Santos-Silva I.

Cancer Epidemiol Biomarkers Prev. 2018 Dec;27(12):1500-1508. doi: 10.1158/1055-9965.EPI-18-0036. Epub 2018 Sep 18.

PMID:
30228153
3.

Reassessing the Association between Circulating Vitamin D and IGFBP-3: Observational and Mendelian Randomization Estimates from Independent Sources.

Tan VY, Biernacka KM, Dudding T, Bonilla C, Gilbert R, Kaplan RC, Qibin Q, Teumer A, Martin RM, Perks CM, Timpson NJ, Holly JMP; PRACTICAL consortium.

Cancer Epidemiol Biomarkers Prev. 2018 Dec;27(12):1462-1471. doi: 10.1158/1055-9965.EPI-18-0113. Epub 2018 Aug 2.

PMID:
30072546
4.

Insulin-like Growth Factor II (IGF-II) in Adipocyte Regulation: Depot-Specific Actions Suggest a Potential Role Limiting Excess Visceral Adiposity.

Alfares MN, Perks CM, Hamilton-Shield JP, Holly JMP.

Am J Physiol Endocrinol Metab. 2018 Jul 24. doi: 10.1152/ajpendo.00409.2017. [Epub ahead of print]

PMID:
30040480
5.

Inhibition of FASN and ERα signalling during hyperglycaemia-induced matrix-specific EMT promotes breast cancer cell invasion via a caveolin-1-dependent mechanism.

Zielinska HA, Holly JMP, Bahl A, Perks CM.

Cancer Lett. 2018 Apr 10;419:187-202. doi: 10.1016/j.canlet.2018.01.028. Epub 2018 Jan 11.

6.

Circulating sex hormones in relation to anthropometric, sociodemographic and behavioural factors in an international dataset of 12,300 men.

Watts EL, Appleby PN, Albanes D, Black A, Chan JM, Chen C, Cirillo PM, Cohn BA, Cook MB, Donovan JL, Ferrucci L, Garland CF, Giles GG, Goodman PJ, Habel LA, Haiman CA, Holly JMP, Hoover RN, Kaaks R, Knekt P, Kolonel LN, Kubo T, Le Marchand L, Luostarinen T, MacInnis RJ, Mäenpää HO, Männistö S, Metter EJ, Milne RL, Nomura AMY, Oliver SE, Parsons JK, Peeters PH, Platz EA, Riboli E, Ricceri F, Rinaldi S, Rissanen H, Sawada N, Schaefer CA, Schenk JM, Stanczyk FZ, Stampfer M, Stattin P, Stenman UH, Tjønneland A, Trichopoulou A, Thompson IM, Tsugane S, Vatten L, Whittemore AS, Ziegler RG, Allen NE, Key TJ, Travis RC.

PLoS One. 2017 Dec 27;12(12):e0187741. doi: 10.1371/journal.pone.0187741. eCollection 2017.

7.

Hyperglycemia Promotes TMPRSS2-ERG Gene Fusion in Prostate Cancer Cells via Upregulating Insulin-Like Growth Factor-Binding Protein-2.

Holly JMP, Broadhurst J, Mansor R, Bahl A, Perks CM.

Front Endocrinol (Lausanne). 2017 Nov 6;8:305. doi: 10.3389/fendo.2017.00305. eCollection 2017.

8.

Developing the WCRF International/University of Bristol Methodology for Identifying and Carrying Out Systematic Reviews of Mechanisms of Exposure-Cancer Associations.

Lewis SJ, Gardner M, Higgins J, Holly JMP, Gaunt TR, Perks CM, Turner SD, Rinaldi S, Thomas S, Harrison S, Lennon RJ, Tan V, Borwick C, Emmett P, Jeffreys M, Northstone K, Mitrou G, Wiseman M, Thompson R, Martin RM.

Cancer Epidemiol Biomarkers Prev. 2017 Nov;26(11):1667-1675. doi: 10.1158/1055-9965.EPI-17-0232. Epub 2017 Oct 4.

9.

Post-diagnosis serum insulin-like growth factors in relation to dietary and lifestyle changes in the Prostate testing for cancer and Treatment (ProtecT) trial.

Er V, Biernacka K, Simpkin AJ, Martin RM, Jeffreys M, Emmett P, Gilbert R, Avery KNL, Walsh E, Davis M, Donovan JL, Neal DE, Hamdy FC, Holly JMP, Lane JA.

Cancer Causes Control. 2017 Aug;28(8):877-888. doi: 10.1007/s10552-017-0910-2. Epub 2017 Jun 23.

10.

Hyperglycaemia-induced resistance to Docetaxel is negated by metformin: a role for IGFBP-2.

Biernacka KM, Persad RA, Bahl A, Gillatt D, Holly JM, Perks CM.

Endocr Relat Cancer. 2017 Jan;24(1):17-30. Epub 2016 Oct 17.

11.

Insulin Receptor Isoform Variations in Prostate Cancer Cells.

Perks CM, Zielinska HA, Wang J, Jarrett C, Frankow A, Ladomery MR, Bahl A, Rhodes A, Oxley J, Holly JM.

Front Endocrinol (Lausanne). 2016 Sep 28;7:132. eCollection 2016.

12.

Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels.

Bonilla C, Lewis SJ, Rowlands MA, Gaunt TR, Davey Smith G, Gunnell D, Palmer T, Donovan JL, Hamdy FC, Neal DE, Eeles R, Easton D, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles GG, Wiklund F, Grönberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Pashayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau S, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park J, Kaneva R, Batra J, Teixeira MR, Pandha H; PRACTICAL consortium, Lathrop M, Martin RM, Holly JM.

Int J Cancer. 2016 Oct 1;139(7):1520-33. doi: 10.1002/ijc.30206. Epub 2016 Jun 23.

13.

Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations.

Christiansen JS, Backeljauw PF, Bidlingmaier M, Biller BM, Boguszewski MC, Casanueva FF, Chanson P, Chatelain P, Choong CS, Clemmons DR, Cohen LE, Cohen P, Frystyk J, Grimberg A, Hasegawa Y, Haymond MW, Ho K, Hoffman AR, Holly JM, Horikawa R, Höybye C, Jorgensen JO, Johannsson G, Juul A, Katznelson L, Kopchick JJ, Lee KO, Lee KW, Luo X, Melmed S, Miller BS, Misra M, Popovic V, Rosenfeld RG, Ross J, Ross RJ, Saenger P, Strasburger CJ, Thorner MO, Werner H, Yuen K.

Eur J Endocrinol. 2016 Jun;174(6):C1-8. doi: 10.1530/EJE-16-0111. Epub 2016 Mar 23.

14.

Blood lipids and prostate cancer: a Mendelian randomization analysis.

Bull CJ, Bonilla C, Holly JM, Perks CM, Davies N, Haycock P, Yu OH, Richards JB, Eeles R, Easton D, Kote-Jarai Z, Amin Al Olama A, Benlloch S, Muir K, Giles GG, MacInnis RJ, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pashayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau S, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park J, Kaneva R, Batra J, Teixeira MR, Micheal A, Pandha H, Smith GD, Lewis SJ, Martin RM; PRACTICAL consortium.

Cancer Med. 2016 Jun;5(6):1125-36. doi: 10.1002/cam4.695. Epub 2016 Mar 19.

15.

Prostate cancer - evidence of exercise and nutrition trial (PrEvENT): study protocol for a randomised controlled feasibility trial.

Hackshaw-McGeagh L, Lane JA, Persad R, Gillatt D, Holly JM, Koupparis A, Rowe E, Johnston L, Cloete J, Shiridzinomwa C, Abrams P, Penfold CM, Bahl A, Oxley J, Perks CM, Martin R.

Trials. 2016 Mar 7;17(1):123. doi: 10.1186/s13063-016-1248-x.

16.

A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk.

Travis RC, Appleby PN, Martin RM, Holly JMP, Albanes D, Black A, Bueno-de-Mesquita HBA, Chan JM, Chen C, Chirlaque MD, Cook MB, Deschasaux M, Donovan JL, Ferrucci L, Galan P, Giles GG, Giovannucci EL, Gunter MJ, Habel LA, Hamdy FC, Helzlsouer KJ, Hercberg S, Hoover RN, Janssen JAMJL, Kaaks R, Kubo T, Le Marchand L, Metter EJ, Mikami K, Morris JK, Neal DE, Neuhouser ML, Ozasa K, Palli D, Platz EA, Pollak M, Price AJ, Roobol MJ, Schaefer C, Schenk JM, Severi G, Stampfer MJ, Stattin P, Tamakoshi A, Tangen CM, Touvier M, Wald NJ, Weiss NS, Ziegler RG, Key TJ, Allen NE.

Cancer Res. 2016 Apr 15;76(8):2288-2300. doi: 10.1158/0008-5472.CAN-15-1551. Epub 2016 Feb 26.

17.

Hyperglycaemia-induced chemoresistance in breast cancer cells: role of the estrogen receptor.

Zeng L, Zielinska HA, Arshad A, Shield JP, Bahl A, Holly JM, Perks CM.

Endocr Relat Cancer. 2016 Feb;23(2):125-34. doi: 10.1530/ERC-15-0507. Epub 2015 Dec 8.

PMID:
26647383
18.

Socioeconomic conditions across life related to multiple measures of the endocrine system in older adults: Longitudinal findings from a British birth cohort study.

Bann D, Hardy R, Cooper R, Lashen H, Keevil B, Wu FC, Holly JM, Ong KK, Ben-Shlomo Y, Kuh D.

Soc Sci Med. 2015 Dec;147:190-9. doi: 10.1016/j.socscimed.2015.11.001. Epub 2015 Nov 6.

19.

Current Understanding of Circulating Tumor Cells - Potential Value in Malignancies of the Central Nervous System.

Adamczyk LA, Williams H, Frankow A, Ellis HP, Haynes HR, Perks C, Holly JM, Kurian KM.

Front Neurol. 2015 Aug 10;6:174. doi: 10.3389/fneur.2015.00174. eCollection 2015. Review.

20.

Epigenetic regulation of insulin-like growth factor binding protein-3 (IGFBP-3) in cancer.

Perks CM, Holly JM.

J Cell Commun Signal. 2015 Jun;9(2):159-66. doi: 10.1007/s12079-015-0294-6. Epub 2015 Apr 29.

21.

Caffeine and Caffeic Acid Inhibit Growth and Modify Estrogen Receptor and Insulin-like Growth Factor I Receptor Levels in Human Breast Cancer.

Rosendahl AH, Perks CM, Zeng L, Markkula A, Simonsson M, Rose C, Ingvar C, Holly JM, Jernström H.

Clin Cancer Res. 2015 Apr 15;21(8):1877-87. doi: 10.1158/1078-0432.CCR-14-1748. Epub 2015 Feb 17.

22.

IGFBP-2/PTEN: A critical interaction for tumours and for general physiology?

Zeng L, Perks CM, Holly JM.

Growth Horm IGF Res. 2015 Jun;25(3):103-7. doi: 10.1016/j.ghir.2015.01.003. Epub 2015 Feb 8. Review.

PMID:
25683897
23.

Changes in insulin-like growth factor-I and -II associated with fat but not lean mass in early old age.

Bann D, Holly JM, Lashen H, Hardy R, Adams J, Kuh D, Ong KK, Ben-Shlomo Y.

Obesity (Silver Spring). 2015 Mar;23(3):692-8. doi: 10.1002/oby.21002. Epub 2015 Feb 3.

24.

Epithelial-to-mesenchymal transition in breast cancer: a role for insulin-like growth factor I and insulin-like growth factor-binding protein 3?

Zielinska HA, Bahl A, Holly JM, Perks CM.

Breast Cancer (Dove Med Press). 2015 Jan 19;7:9-19. doi: 10.2147/BCTT.S43932. eCollection 2015. Review.

25.

Role of IGF-I, IGF-II and IGFBP-3 in lung function of males: the Caerphilly Prospective Study.

Green CJ, Holly JM, Bolton CE, Bayer A, Ebrahim S, Gallacher J, Ben-Shlomo Y.

Int J Mol Epidemiol Genet. 2014 May 29;5(2):112-9. eCollection 2014.

26.

Effects of physiological levels of the green tea extract epigallocatechin-3-gallate on breast cancer cells.

Zeng L, Holly JM, Perks CM.

Front Endocrinol (Lausanne). 2014 May 7;5:61. doi: 10.3389/fendo.2014.00061. eCollection 2014.

27.

The role of IGF-I, IGF-II, and IGFBP-3 in male cognitive aging and dementia risk: the Caerphilly Prospective Study.

Green CJ, Holly JM, Bayer A, Fish M, Ebrahim S, Gallacher J, Ben-Shlomo Y.

J Alzheimers Dis. 2014;41(3):867-75. doi: 10.3233/JAD-132183.

PMID:
24705546
28.

Loss of PTEN expression is associated with IGFBP2 expression, younger age, and late stage in triple-negative breast cancer.

Dean SJ, Perks CM, Holly JM, Bhoo-Pathy N, Looi LM, Mohammed NA, Mun KS, Teo SH, Koobotse MO, Yip CH, Rhodes A.

Am J Clin Pathol. 2014 Mar;141(3):323-33. doi: 10.1309/AJCPR11DEAYPTUSL.

PMID:
24515759
29.

Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2.

Biernacka KM, Uzoh CC, Zeng L, Persad RA, Bahl A, Gillatt D, Perks CM, Holly JM.

Endocr Relat Cancer. 2013 Sep 11;20(5):741-51. doi: 10.1530/ERC-13-0077. Print 2013 Oct.

PMID:
23959956
30.

Epithelial cancers in the post-genomic era: should we reconsider our lifestyle?

Holly JM, Zeng L, Perks CM.

Cancer Metastasis Rev. 2013 Dec;32(3-4):673-705. doi: 10.1007/s10555-013-9445-5. Review.

31.

Insulin-like growth factor binding protein-3 (IGFBP-3) plays a role in the anti-tumorigenic effects of 5-Aza-2'-deoxycytidine (AZA) in breast cancer cells.

Zeng L, Jarrett C, Brown K, Gillespie KM, Holly JM, Perks CM.

Exp Cell Res. 2013 Aug 15;319(14):2282-95. doi: 10.1016/j.yexcr.2013.06.011. Epub 2013 Jun 26.

PMID:
23810988
32.

Insulin-like growth factor binding protein 2 (IGFBP-2) promotes growth and survival of breast epithelial cells: novel regulation of the estrogen receptor.

Foulstone EJ, Zeng L, Perks CM, Holly JM.

Endocrinology. 2013 May;154(5):1780-93. doi: 10.1210/en.2012-1970. Epub 2013 Mar 20.

PMID:
23515291
33.

Insulin-like growth factor-II is produced by, signals to and is an important survival factor for the mature podocyte in man and mouse.

Hale LJ, Welsh GI, Perks CM, Hurcombe JA, Moore S, Hers I, Saleem MA, Mathieson PW, Murphy AJ, Jeansson M, Holly JM, Hardouin SN, Coward RJ.

J Pathol. 2013 May;230(1):95-106. doi: 10.1002/path.4165. Epub 2013 Mar 21.

PMID:
23299523
34.

Insulin-like growth factors (IGFs) and IGF-binding proteins in active monitoring of localized prostate cancer: a population-based observational study.

Rowlands MA, Tilling K, Holly JM, Metcalfe C, Gunnell D, Lane A, Davis M, Donovan J, Hamdy F, Neal DE, Martin RM.

Cancer Causes Control. 2013 Jan;24(1):39-45. doi: 10.1007/s10552-012-0087-7. Epub 2012 Oct 21.

PMID:
23085814
35.

Role of the IGF axis in prostate cancer.

Biernacka KM, Perks CM, Holly JM.

Minerva Endocrinol. 2012 Jun;37(2):173-85. Review.

PMID:
22691890
36.

Insulin-like growth factors in health and disease. Preface.

Perks CM, Holly JM.

Endocrinol Metab Clin North Am. 2012 Jun;41(2):xv-xvi. doi: 10.1016/j.ecl.2012.04.021. Epub 2012 May 15. No abstract available.

PMID:
22682641
37.

Insulin-like growth factor physiology: what we have learned from human studies.

Holly JM, Perks CM.

Endocrinol Metab Clin North Am. 2012 Jun;41(2):249-63, v. doi: 10.1016/j.ecl.2012.04.009. Epub 2012 May 8. Review.

PMID:
22682629
38.

Childhood milk consumption is associated with better physical performance in old age.

Birnie K, Ben-Shlomo Y, Gunnell D, Ebrahim S, Bayer A, Gallacher J, Holly JM, Martin RM.

Age Ageing. 2012 Nov;41(6):776-84. doi: 10.1093/ageing/afs052. Epub 2012 Apr 26.

39.

A cross-sectional analysis of the association between diet and insulin-like growth factor (IGF)-I, IGF-II, IGF-binding protein (IGFBP)-2, and IGFBP-3 in men in the United Kingdom.

Young NJ, Metcalfe C, Gunnell D, Rowlands MA, Lane JA, Gilbert R, Avery KN, Davis M, Neal DE, Hamdy FC, Donovan J, Martin RM, Holly JM.

Cancer Causes Control. 2012 Jun;23(6):907-17. doi: 10.1007/s10552-012-9961-6. Epub 2012 Apr 21.

PMID:
22527168
40.

Higher levels of IGF-I and adrenal androgens at age 8 years are associated with earlier age at menarche in girls.

Thankamony A, Ong KK, Ahmed ML, Ness AR, Holly JM, Dunger DB.

J Clin Endocrinol Metab. 2012 May;97(5):E786-90. doi: 10.1210/jc.2011-3261. Epub 2012 Mar 14.

41.

Associations of insulin and insulin-like growth factors with physical performance in old age in the Boyd Orr and Caerphilly studies.

Birnie K, Ben-Shlomo Y, Holly JM, Gunnell D, Ebrahim S, Bayer A, Gallacher J, Martin RM.

PLoS One. 2012;7(1):e30096. doi: 10.1371/journal.pone.0030096. Epub 2012 Jan 10.

42.

Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer.

Rowlands MA, Holly JM, Hamdy F, Phillips J, Goodwin L, Marsden G, Gunnell D, Donovan J, Neal DE, Martin RM.

Cancer Causes Control. 2012 Feb;23(2):347-54. doi: 10.1007/s10552-011-9883-8. Epub 2011 Dec 20.

PMID:
22183619
43.

Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT.

Rowlands MA, Holly JM, Gunnell D, Donovan J, Lane JA, Hamdy F, Neal DE, Oliver S, Smith GD, Martin RM.

Cancer Res. 2012 Jan 15;72(2):503-15. doi: 10.1158/0008-5472.CAN-11-1601. Epub 2011 Nov 21.

44.

Prospective study of insulin-like growth factor-I, insulin-like growth factor-binding protein 3, genetic variants in the IGF1 and IGFBP3 genes and risk of coronary artery disease.

Ricketts SL, Rensing KL, Holly JM, Chen L, Young EH, Luben R, Ashford S, Song K, Yuan X, Dehghan A, Wright BJ, Waterworth DM, Mooser V; GEMS Investigators, Waeber G, Vollenweider P, Epstein SE, Burnett MS, Devaney JM, Hakonarson HH, Rader DJ, Reilly MP, Danesh J, Thompson SG, Dunning AM, van Duijn CM, Samani NJ, McPherson R, Wareham NJ, Khaw KT, Boekholdt SM, Sandhu MS.

Int J Mol Epidemiol Genet. 2011 Aug 30;2(3):261-85. Epub 2011 Aug 3.

45.

Hormonal mechanisms underlying the relationship between obesity and breast cancer.

Perks CM, Holly JM.

Endocrinol Metab Clin North Am. 2011 Sep;40(3):485-507, vii. doi: 10.1016/j.ecl.2011.05.010. Epub 2011 Jul 8. Review.

PMID:
21889716
46.

Green tea extract (epigallocatechin-3-gallate) reduces efficacy of radiotherapy on prostate cancer cells.

Thomas F, Holly JM, Persad R, Bahl A, Perks CM.

Urology. 2011 Aug;78(2):475.e15-21. doi: 10.1016/j.urology.2011.03.031. Epub 2011 Jun 14.

PMID:
21676444
47.

Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel.

Uzoh CC, Holly JM, Biernacka KM, Persad RA, Bahl A, Gillatt D, Perks CM.

Br J Cancer. 2011 May 10;104(10):1587-93. doi: 10.1038/bjc.2011.127. Epub 2011 Apr 12.

48.

Milk and linear growth: programming of the igf-I axis and implication for health in adulthood.

Martin RM, Holly JM, Gunnell D.

Nestle Nutr Workshop Ser Pediatr Program. 2011;67:79-97. doi: 10.1159/000325577. Epub 2011 Feb 16. Review.

PMID:
21335992
49.

Intrinsic, Pro-Apoptotic Effects of IGFBP-3 on Breast Cancer Cells are Reversible: Involvement of PKA, Rho, and Ceramide.

Perks CM, Burrows C, Holly JM.

Front Endocrinol (Lausanne). 2011 May 16;2:13. doi: 10.3389/fendo.2011.00013. eCollection 2011.

50.

Genome-wide association meta-analysis of cortical bone mineral density unravels allelic heterogeneity at the RANKL locus and potential pleiotropic effects on bone.

Paternoster L, Lorentzon M, Vandenput L, Karlsson MK, Ljunggren O, Kindmark A, Mellstrom D, Kemp JP, Jarett CE, Holly JM, Sayers A, St Pourcain B, Timpson NJ, Deloukas P, Davey Smith G, Ring SM, Evans DM, Tobias JH, Ohlsson C.

PLoS Genet. 2010 Nov 18;6(11):e1001217. doi: 10.1371/journal.pgen.1001217.

Supplemental Content

Loading ...
Support Center